Zymeworks Inc.

Stocks

Market Closed - Nasdaq 00:00:00 31/10/2026 +04			5-day change	1st Jan Change
28.61 ^USD	-0.35%		+1.38%	+8.66%

10-27	Zymeworks Inc. - Special Call
10-24	Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026	CI

Published on 10/27/2026 at 06:20 pm +04 - Modified on 10/27/2026 at 11:20 pm +04

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by. Welcome to Zymeworks conference call and webcast to discuss Zymeworks' portfolio updates. [Operator Instructions] I would

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-27	Zymeworks Inc. - Special Call
10-24	Zymeworks Inc. Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate Zw191 At ESMO Congress 2026	CI
10-23	Zymeworks Inc. Enters Into An Exclusive Global License And Collaboration Agreement With F. Hoffmann-La Roche Ltd And Hoffmann-La Roche Inc. For ZW209, A Trispecific T Cell Engager Targeting DLL3	CI
10-23	Zymeworks, Roche Enter Collaboration to Develop Experimental Lung Cancer Drug	DJ
10-23	Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones	MT
10-23	Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal	RE
10-19	Zymeworks Inc. Announces Appointment of Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma, Effective October 19, 2026	CI
10-08	Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal	MT
09-28	Zymeworks Inc., Theravance Biopharma, Inc. - M&A Call
09-28	Zymeworks Inc. Updates Earnings Guidance for the Year 2026	CI
09-28	Zymeworks Appoints Stuart Knight as Executive Vice President & Chief Information Officer	CI
09-28	Zymeworks Completes Acquisition of Theravance Biopharma; Updates 2026 Guidance	MT
09-28	(ZYME) Zymeworks Expects 2026 Revenue Range $278M - $292M	MT
09-24	Zymeworks Completes Acquisition of Theravance Biopharma	MT
09-23	Zymeworks Inc. acquired Theravance Biopharma, Inc..	CI

Duration

Period

Sector